The reliability of radiographic sacroiliitis assessment is known to be poor. Expert readers –as opposed to evaluation by local rheumatologists or radiologists– usually produce more reliable results, but they are not available in many locations. “We see a big discrepancy between the local and central assessment of sacroiliitis reaching sometimes half of the cases,” Prof. Denis Poddubnyy (Charité Universitätsmedizin Berlin, Germany) said. Can artificial intelligence support the diagnosis?
For this study, Prof. Poddubnyy and his team used conventional radiographs of sacroiliac joints from 2 independent cohorts of patients with axial spondylarthritis (axSpA), including 1,669 radiographs used to train and validate the neural network, and 100 radiographs used as a test dataset [1]. All radiographs went through reading by both humans and the artificial neural network. Readers used the modified New York criteria to determine either the presence or absence of definite radiographic sacroiliitis. The researchers then analysed whether the human readers or artificial neural network agreed.
The artificial neural network achieved excellent performance in accurately recognising definite radiographic sacroiliitis in these patients, with high ratings of sensitivity and specificity (0.90 and 0.93 for the validation and 0.87 and 0.97 for the test set). This artificial intelligence-driven model could enable accurate detection of sacroiliitis for both diagnosis of patients in the clinic and classification of axSpA when selecting patients for clinical trials.
“I do think that the developed artificial neural network might be helpful in clinical practice,” Prof. Poddubnyy concluded. This approach will now be tested for the assessment of MRI of sacroiliac joints, which would be especially relevant for the diagnosis of axSpA in an early stage.
- Bressem KK, et al. Development and validation of an artificial intelligence approach for the detection of radiographic sacroiliitis. 2018, ACR Convergence 2020, 5-9 Nov.
Posted on
Previous Article
« Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms Next Article
Signs of benefit for T2T in axial spondyloarthritis »
« Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms Next Article
Signs of benefit for T2T in axial spondyloarthritis »
Table of Contents: ACR 2020
Featured articles
Late-Breaking News
Gout treatment with febuxostat: no higher cardiovascular mortality
New agent with great potential for the treatment of giant cell arteritis in the pipeline
Autotaxin inhibitor successful in the first trial in diffuse cutaneous systemic sclerosis
JAK inhibition as a treatment option for ankylosing spondylitis
Spotlight on Rheumatoid Arthritis
Persuasive long-term results for JAK inhibition in rheumatoid arthritis
Rheumatoid arthritis: new EULAR treatment guidelines
Rheumatoid arthritis and interstitial lung disease: a deadly combination
COVID-19 – What Rheumatologists Need to Know
COVID-19 in patients with rheumatic disease: most report mild disease
Poor disease control: a risk factor for severe COVID-19
No heightened outcome risk for rheumatic patients with COVID-19
What Is Hot in Lupus Nephritis?
Lupus nephritis biomarkers: moving toward an omic-driven approach
Lupus nephritis: new therapies on the horizon in 2020
Spondyloarthritis – The Beat Goes On
Artificial intelligence can help in the diagnosis of axSPA
Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms
Promising novel treatment option for psoriatic arthritis
How to Diagnose Large Vessel Vasculitis: Promises and Pitfalls
How to choose imaging modalities in large vessel vasculitis
Diagnosis of large vessel vasculitis with imaging
Osteoarthritis – Novel Developments
Knee osteoarthritis patients with indicators of inflammation could profit from methotrexate
Anticoagulation with vitamin K antagonist is associated with risk of knee and hip replacement
Osteoporosis – New Data
Bisphosphonate use: Asian American women have a smaller treatment benefit
Inflammatory disease as a risk factor for fractures
Best of the Posters
No progression of osteoarthritis with corticosteroid injections
Hydroxychloroquine use: no indication for arrhythmias in RA and SLE patients
Children with rheumatic disease have no greater risk of a COVID-19 infection
Insufficient antimalarial supply for rheumatic disease treatment in the early COVID-19 pandemic
Related Articles
August 11, 2021
New target to dial down inflammation and pain discovered
September 4, 2019
Short methotrexate stop is safe in patients with RA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com